228 related articles for article (PubMed ID: 35712486)
1. Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.
Chen X; Li W; Wu X; Zhao F; Wang D; Wu H; Gu Y; Li X; Qian X; Hu J; Li C; Xia Y; Rao J; Dai X; Shao Q; Tang J; Li X; Shu Y
Front Oncol; 2022; 12():909035. PubMed ID: 35712486
[TBL] [Abstract][Full Text] [Related]
2. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.
Chu T; Zhang W; Zhang B; Zhong R; Zhang X; Gu A; Shi C; Wang H; Xiong L; Lu J; Qian J; Zhang Y; Dong Y; Teng J; Gao Z; Wang W; Shen Y; Nie W; Lim JU; Mehta HJ; Neal JW; Lou Y; Xu J; Zhong H; Han B
Transl Lung Cancer Res; 2022 Jul; 11(7):1394-1404. PubMed ID: 35958322
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1-Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial.
Xu Q; Wang J; Sun Y; Lin Y; Liu J; Zhuo Y; Huang Z; Huang S; Chen Y; Chen L; Ke M; Li L; Li Z; Pan J; Song Y; Liu R; Chen C
J Clin Oncol; 2022 Jun; 40(16):1795-1805. PubMed ID: 35192397
[TBL] [Abstract][Full Text] [Related]
5. Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.
Chu T; Zhong R; Zhong H; Zhang B; Zhang W; Shi C; Qian J; Zhang Y; Chang Q; Zhang X; Dong Y; Teng J; Gao Z; Qiang H; Nie W; Zhao Y; Han Y; Chen Y; Han B
J Thorac Oncol; 2021 Apr; 16(4):643-652. PubMed ID: 33524601
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study.
Cai M; Huang W; Liang W; Guo Y; Liang L; Lin L; Xie L; Zhou J; Chen Y; Cao B; Wu J; Zhu K
Liver Int; 2024 Apr; 44(4):920-930. PubMed ID: 38291865
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib Combined With Toripalimab as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Prospective, Multicenter, Phase II Study.
Zhang CS; Zeng ZM; Zhuo MY; Luo JR; Zhuang XH; Xu JN; Zeng J; Ma J; Lin HF
Oncologist; 2023 Dec; 28(12):e1239-e1247. PubMed ID: 37329569
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
10. Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study.
Li D; Xu L; Ji J; Bao D; Hu J; Qian Y; Zhou Y; Chen Z; Li D; Li X; Zhang X; Wang H; Yi C; Shi M; Pang Y; Liu S; Xu X
Front Immunol; 2022; 13():944062. PubMed ID: 36091003
[TBL] [Abstract][Full Text] [Related]
11. Sintilimab plus anlotinib as second or further-line therapy for extensive disease small cell lung cancer: a phase 2 investigator-initiated non-randomized controlled trial.
Ma S; He Z; Liu Y; Wang L; Yang S; Wu Y; Chen H; Wu Y; Wang Q
EClinicalMedicine; 2024 Apr; 70():102543. PubMed ID: 38516099
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China.
Chen XQ; Zhao YX; Zhang CL; Wang XT; Zhang X; Chen X; Yuan CW; Zhao Q; Chen XJ
Drug Des Devel Ther; 2022; 16():1483-1493. PubMed ID: 35607597
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study.
Zhao L; Chang N; Shi L; Li F; Meng F; Xie X; Xu Z; Wang F
Heliyon; 2022 Jun; 8(6):e09538. PubMed ID: 35706954
[TBL] [Abstract][Full Text] [Related]
14. A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma.
Li N; Wu T; Hong YG; Guo YZ; Cheng YF; Ma YJ; Bie LY; Cui DH; Gao XH; Tan BX; Li BS; Luo SX; Wang JS
BMC Med; 2022 Dec; 20(1):472. PubMed ID: 36482345
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
Qiao Q; Han C; Ye S; Li J; Shao G; Bai Y; Xu A; Sun M; Wang W; Wu J; Huang M; Song L; Huang L; Liu T; Liu W; Wang ZM; Li B; Xia M; Bai L
Front Immunol; 2023; 14():1238667. PubMed ID: 37942328
[TBL] [Abstract][Full Text] [Related]
16. Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study.
Wang L; Wang H; Cui Y; Liu M; Jin K; Xu D; Wang K; Xing B
Front Oncol; 2023; 13():1115109. PubMed ID: 36874115
[TBL] [Abstract][Full Text] [Related]
17. Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203).
Han C; Ye S; Hu C; Shen L; Qin Q; Bai Y; Yang S; Bai C; Zang A; Jiao S; Bai L
Front Oncol; 2021; 11():684867. PubMed ID: 34327136
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world.
Xie D; Sun Q; Wang X; Zhou J; Fan J; Ren Z; Gao Q
Ann Transl Med; 2021 Apr; 9(8):652. PubMed ID: 33987350
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
Li JX; Deng WX; Huang ST; Lin XF; Long MY; Zhang J; Su TS; Li LQ; Pang YD; Liang CF; Zhou HM; Lu HY; Liang SX; Xiang BD
Radiat Oncol; 2022 Jun; 17(1):106. PubMed ID: 35690773
[TBL] [Abstract][Full Text] [Related]
20. Phase Ib study of anlotinib in combination with anti-PD-L1 antibody (TQB2450) in patients with advanced acral melanoma.
Du Y; Dai J; Mao L; Wei X; Bai X; Chen L; Lin J; Chi Z; Cui C; Sheng X; Lian B; Tang B; Wang X; Yan X; Li S; Zhou L; Guo J; Chen Y; Si L
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):93-101. PubMed ID: 37625814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
